🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,762 results for “CTI” Clear

  1. SIBP-A13 formulation for injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  2. SOF/VEL/VOX

    Gilead Sciences Ireland UC

    HCV Infection

    phase 1 small molecule completed

    1 trial

  3. SSP-004184

    Takeda

    Impaired Renal Function

    phase 1 small molecule completed

    1 trial

  4. SSS67 Injection

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Healthy

    phase 1 small molecule active

    1 trial

  5. Safety Assessment of 10-Day Daily Bucco-Oral Administration of Transfer Factor in Healthy Adult Human Subjects

    s.r.o.

    healthy subjects, It is used in conditions with decreased immunity to enhance it e.g. in case of recurrent and chronic viral infections.

    phase 1 other active

    1 trial

  6. Safety, Tolerability and Pharmacokinetic Profile of TPT0301 in Healthy Volunteers

    Alphapharm Pty Ltd

    adjunctive neuropathic pain

    phase 1 other active

    1 trial

  7. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AB-101 Following Oral Administration in Healthy and Chronic Hepatitis B Subjects

    Arbutus Biopharma Corp

    Chronic hepatitis B virus Infection

    phase 1 other active

    1 trial

  8. Saline

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Addiction

    phase 1 small molecule completed

    1 trial

  9. Shenkang decoction

    The First People's Hospital of Lianyungang

    Chronic Renal Failure

    phase 1 small molecule completed

    1 trial

  10. Simvastatin

    Aurinia Pharmaceuticals

    Drug-drug Interaction

    phase 1 small molecule completed

    1 trial

  11. Single Dose Pharmacokinetics and Relative Bioavailability of Sayana Press via Upper Arm Injection Relative to Anterior Thigh and Abdomen

    Pfizer Australia Pty Ltd

    long-term female contraception

    phase 1 other active

    1 trial

  12. Single dose intravenous injection of BBM 002

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hemophilia A

    phase 1 gene therapy active

    1 trial

  13. Sinovac PCV24 formulation 1

    Sinovac Research and Development Co.,

    Pneumococcal Infectious Disease

    phase 1 mab completed

    2 trials

  14. Sotagliflozin (SOTA) followed by 3 drugs in a random order

    LEXICON PHARMACEUTICALS, INC.

    Platelet Function and Reactivity Tests

    phase 1 small molecule active

    1 trial

  15. Sotrovimab

    Vir Biotechnology

    COVID-19 Infection

    phase 1 mab terminated

    1 trial

  16. Spinraza 12 mg solution for injection

    Biogen

    Spinal Muscular Atrophy

    phase 1 small molecule active

    1 trial

  17. Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2

    Arrowhead Pharmaceuticals Ireland Limited

    spinocerebellar ataxia type 2

    phase 1 other active

    1 trial

  18. Study of Repotrectinib and CYP450 probe Cocktail in Patients with locally advanced or Metastatic Tyrosine Kinase Inhibitors (TKI)-Pretreated ROS1-Positive Non-small Cell Lung Cancer (NSCLC)

    Bristol-Myers Squibb Australia Pty Ltd

    Non-small Cell Lung Cancer (NSCLC)

    phase 1 other active

    1 trial

  19. Study of safety and antitumor activity of GEN1056 in participants with advanced solid tumors

    Genmab A/S

    Advanced solid tumors

    phase 1 other active

    1 trial

  20. Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

    AbbVie Deutschland GmbH & Co. KG

    Non-Hodgkin's Lymphoma

    phase 1 other active

    1 trial

  21. Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

    AbbVie Deutschland GmbH & Co. KG

    Select B-Cell malignancies.

    phase 1 other active

    1 trial

  22. Study to evaluate the addition of an experimental drug, CC-90010, to the usual treatment of brain cancer after surgery

    Celgene Europe Limited

    Subjects with newly diagnosed WHO Grade IV glioblastoma (ndGBM) who have undergone complete or partial tumor resection

    phase 1 other active

    1 trial

  23. Study to evaluate the safety, tolerability, maximum tolerated dose and clinical activity of TNB-383B when given to patients with multiple myeloma

    AbbVie Deutschland GmbH & Co. KG

    Relapsed or refractory multiple myeloma

    phase 1 other active

    1 trial

  24. Subconjunctival aflibercept

    Regeneron UK Limited

    Corneal Neovascularization

    phase 1 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources